Nuvo Pharmaceuticals™ Announces 2016 Second Quarter Results
PR Newswire - Wed Aug 10, 4:00PM CDT
Q2 net income increases to $2.5 million or $0.22 basic earnings per share - - Positive cash from operating activities of $2.1 million in the quarter -
NRI.TO: 7.15 (+0.10), HZNP: 22.82 (-0.34)
Nuvo Pharmaceuticals(TM) Announces 2016 Second Quarter Results
CNW Group - Wed Aug 10, 4:00PM CDT
- Q2 net income increases to $2.5 million or $0.22 basic earnings per share -- Positive cash from operating activities of $2.1 million in the quarter -
NRI.TO: 7.15 (+0.10), HZNP: 22.82 (-0.34)
Nuvo Pharmaceuticals™ Announces Director Election Results of its Annual General Meeting
PR Newswire - Tue Jun 07, 2:42PM CDT
Nuvo Pharmaceuticals Inc. (Nuvo or the Company) (TSX:NRI) a commercial healthcare company with a portfolio of commercial products and pharmaceutical manufacturing capabilities, today announced that at its 2016 Annual Meeting of Shareholders held in Toronto, all nominees listed in the management proxy circular dated May 4, 2016 were elected as directors of the Company.
NRI.TO: 7.15 (+0.10), HZNP: 22.82 (-0.34)
Nuvo Pharmaceuticals(TM) Announces Director Election Results of its Annual General Meeting
CNW Group - Tue Jun 07, 2:42PM CDT
Nuvo Pharmaceuticals Inc. (Nuvo or the Company) (TSX:NRI) a commercial healthcare company with a portfolio of commercial products and pharmaceutical manufacturing capabilities, today announced that at its 2016 Annual Meeting of Shareholders held in Toronto, all nominees listed in the management proxy circular dated May 4, 2016 were elected as directors of the Company.
NRI.TO: 7.15 (+0.10), HZNP: 22.82 (-0.34)
Nuvo Pharmaceuticals™ Announces 2016 First Quarter Results
PR Newswire - Wed May 11, 4:00PM CDT
Revenue and gross margin increase - - Nuvo to Host Conference Call/Audio Webcast May 12th at 8:30 a.m. ET -
NRI.TO: 7.15 (+0.10), HZNP: 22.82 (-0.34)
Nuvo Pharmaceuticals™ Inc. announces appointment of Vice President, Business Development
PR Newswire - Mon Apr 04, 6:30AM CDT
Nuvo Pharmaceuticals Inc. (TSX:NRI) (Nuvo or the Company) today announced that Jesse Ledger has been appointed to the newly created position of Vice President, Business Development. Mr. Ledger will be responsible for all business development activities with an initial focus on maximizing the value of the Company's Pennsaid 2% franchise through global out-licensing.
NRI.TO: 7.15 (+0.10), HZNP: 22.82 (-0.34), ARLZ: 5.21 (+0.01), POZN: 5.94 (-0.43)